ENLV
Enlivex Therapeutics Ltd
NASDAQ: ENLV · HEALTHCARE · BIOTECHNOLOGY
$1.95
-13.33% today
Updated 2026-07-30
Market cap
$70.69M
P/E ratio
0.01
P/S ratio
—
EPS (TTM)
$364.84
Dividend yield
—
52W range
$4 – $32
Volume
0.4M
Enlivex Therapeutics Ltd (ENLV) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
+43.4%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+0.0%
Most recent quarter
When is the next earnings report?
Reporting date
June 30, 2026
Consensus EPS estimate
$-0.02
Fiscal period ending
2026-06-30
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-0.8%
Last 3 reports
Positive reaction rate
0%
0 of 3 quarters
Largest single-day move
-1.5%
2025-11-14
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-06-26 | $-0.15 | -650.0% | $0.58 | $0.58 | -0.1% |
| 2026-03-25 | $-0.05 | +64.0% | $1.10 | $1.09 | -0.9% |
| 2025-11-14 | $-0.12 | +18.7% | $0.99 | $0.98 | -1.5% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-06-30 | $-0.02 | — | — | — | — |
| 2026-03-31 | $-0.02 | $-0.15 | -650.0% | — | — |
| 2025-12-31 | $-0.14 | $-0.05 | +64.0% | — | — |
| 2025-09-30 | $-0.14 | $-0.12 | +18.7% | — | — |
| 2025-06-30 | $-0.15 | $-0.08 | +47.6% | — | — |
| 2025-03-31 | $-0.16 | $-0.15 | +6.3% | — | — |
| 2024-12-31 | $-0.16 | $-0.23 | -43.8% | — | — |
| 2024-09-30 | $-0.20 | $-0.16 | +17.9% | — | — |
| 2024-06-30 | $-0.15 | $-0.16 | -6.7% | — | — |
| 2024-03-31 | $-0.25 | $-0.22 | +12.0% | — | — |
| 2023-12-31 | $-0.28 | $-0.48 | -71.4% | — | — |
Frequently asked questions
When does Enlivex Therapeutics Ltd report next earnings?
Enlivex Therapeutics Ltd (ENLV) is scheduled to report earnings on June 30, 2026. The consensus EPS estimate is $-0.02.
Has Enlivex Therapeutics Ltd beaten earnings estimates?
Enlivex Therapeutics Ltd has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, averaging a +43.4% surprise over the last 3. A consistent beat record suggests management guides conservatively and the business has predictable momentum, which tends to support the stock through earnings season.
How does ENLV stock react to earnings?
ENLV has moved an average of -0.8% the day after earnings over its last 3 reports, finishing higher after 0 of them. Next-day moves show how the market digests results in the short term, and repeated dips on strong reports usually mean expectations were already priced in.